AbbVie
ABBV
#26
Rank
NZ$680.67 B
Marketcap
NZ$384.96
Share price
0.30%
Change (1 day)
3.01%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

Earnings for AbbVie (ABBV)

Earnings in 2025 (TTM): NZ$2.68 Billion

According to AbbVie's latest financial reports the company's current earnings are NZ$59.64 Billion. In 2024 the company made an earning of NZ$6.28 Billion a decrease over its 2023 earnings that were of NZ$10.56 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for AbbVie from 2011 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$2.68 B-57.21%
2024 NZ$6.28 B-40.54%
2023 NZ$10.56 B-53.62%
2022 NZ$22.78 B3.76%
2021 NZ$21.96 B282.25%
2020 NZ$5.74 B-59.67%
2019 NZ$14.24 B62.13%
2018 NZ$8.78 B-32.74%
2017 NZ$13.06 B-1.99%
2016 NZ$13.33 B18.65%
2015 NZ$11.23 B180.5%
2014 NZ$4.00 B-55.57%
2013 NZ$9.01 B-6.86%
2012 NZ$9.67 B56.05%
2011 NZ$6.20 B

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$20.03 B 613.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$38.04 B 1,255.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$13.93 B 396.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$3.21 B 14.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$16.71 B 495.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$13.58 B 383.92%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$22.13 B 688.55%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$15.76 B 461.62%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$0.98 B-64.87%๐Ÿ‡บ๐Ÿ‡ธ USA